Subacute cutaneous lupus erythematosus
ICD-10 L93.1 · ICD-11 EB50

Treatment of Subacute Cutaneous Lupus Erythematosus with Localized Cutaneous Skin Lesions

This protocol addresses subacute cutaneous lupus erythematosus (SCLE) in patients presenting with localized cutaneous lupus erythematosus skin lesions — a clinically important subgroup where the extent and distribution of involvement directly shapes therapeutic choices.

Clinical Scenario

Patients in this scenario have SCLE confined to localized skin areas. Topical therapies are central to managing localized cutaneous lupus erythematosus lesions, supported by evidence across CLE subtypes, though controlled studies remain limited in number.

Treatment Approach
For patients with localized SCLE lesions where initial antimalarial monotherapy proves insufficient, a specific combination antimalarial strategy — adding a second agent — is recommended to achieve synergistic efficacy. Full regimen details, sequencing, contraindication pathways, and dosing are available in the complete protocol below.
Instant Access to Structured Evidence-Based Regimens

References

  1. Topical corticosteroids are the mainstay in the treatment of localized CLE being effective in all subtypes (Figure 1), but only few controlled studies have been published proving their efficacy.
  2. If monotherapy with HCQ or CQ is not successful, quinacrine (100 mg/day) may be added, resulting in synergistic efficacy, without increasing the risk of retinopathy.
  3. In refractory cases, we recommend to add quinacrine to either HCQ or CQ.
  4. In cases of contraindication for HCQ or CQ (e.g., retinopathy), monotherapy with quinacrine is recommended.
View source ↗